$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.

2015 Q3 Form 10-Q Financial Statement

#000119312515366818 Filed on November 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.910M $2.300M
YoY Change 26.52% 5.02%
% of Gross Profit
Research & Development $2.864M $1.358M
YoY Change 110.91% 4.74%
% of Gross Profit
Depreciation & Amortization $160.0K $170.0K
YoY Change -5.88% 6.25%
% of Gross Profit
Operating Expenses $5.779M $3.826M
YoY Change 51.05% 195.07%
Operating Profit -$5.779M -$3.826M
YoY Change 51.05% 4.81%
Interest Expense $0.00 $80.00K
YoY Change -100.0% -108.89%
% of Operating Profit
Other Income/Expense, Net -$1.000K $77.00K
YoY Change -101.3% -108.53%
Pretax Income -$5.780M -$3.750M
YoY Change 54.13% -17.58%
Income Tax
% Of Pretax Income
Net Earnings -$5.780M -$3.749M
YoY Change 54.17% -17.66%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$28.25K -$20.94K
COMMON SHARES
Basic Shares Outstanding 204.6M shares 180.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.88M $17.77M
YoY Change 6.25% 115.39%
Cash & Equivalents $18.88M $17.77M
Short-Term Investments
Other Short-Term Assets $1.066M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.95M $17.77M
YoY Change 12.24% 114.17%
LONG-TERM ASSETS
Property, Plant & Equipment $88.64K $95.56K
YoY Change -7.24% 200.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.00K $27.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $6.654M $3.874M
YoY Change 71.77% -13.55%
TOTAL ASSETS
Total Short-Term Assets $19.95M $17.77M
Total Long-Term Assets $6.654M $3.874M
Total Assets $26.60M $21.65M
YoY Change 22.9% 69.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $970.0K $480.0K
YoY Change 102.08% 140.0%
Accrued Expenses $1.090M $400.0K
YoY Change 172.5% 17.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.075M $881.1K
YoY Change 135.47% 62.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $1.230M
YoY Change -100.0% -64.96%
Total Long-Term Liabilities $0.00 $1.230M
YoY Change -100.0% -64.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.075M $881.1K
Total Long-Term Liabilities $0.00 $1.230M
Total Liabilities $2.075M $2.108M
YoY Change -1.6% -48.03%
SHAREHOLDERS EQUITY
Retained Earnings -$171.1M -$157.1M
YoY Change 8.93% 21.36%
Common Stock $204.6K $180.3K
YoY Change 13.5% 28.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.53M $19.54M
YoY Change
Total Liabilities & Shareholders Equity $26.60M $21.65M
YoY Change 22.9% 69.38%

Cashflow Statement

Concept 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$5.780M -$3.749M
YoY Change 54.17% -17.66%
Depreciation, Depletion And Amortization $160.0K $170.0K
YoY Change -5.88% 6.25%
Cash From Operating Activities -$4.230M -$3.400M
YoY Change 24.41% 23.19%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$70.00K
YoY Change -85.71% 600.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$70.00K
YoY Change -85.71% 600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.120M
YoY Change -100.0% -51.17%
NET CHANGE
Cash From Operating Activities -4.230M -3.400M
Cash From Investing Activities -10.00K -70.00K
Cash From Financing Activities 0.000 3.120M
Net Change In Cash -4.240M -350.0K
YoY Change 1111.43% -109.67%
FREE CASH FLOW
Cash From Operating Activities -$4.230M -$3.400M
Capital Expenditures -$10.00K -$70.00K
Free Cash Flow -$4.220M -$3.330M
YoY Change 26.73% 21.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
33334 shares
CY2013Q2 us-gaap Litigation Reserve
LitigationReserve
100000
CY2014Q2 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2014Q2 pvct Reimbursement Receivable Percentage
ReimbursementReceivablePercentage
0.25 pure
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3036218 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
372000 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17773680
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204637136 shares
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
204637136 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204637136 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
292356
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
24529437
CY2015Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
972693
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227582
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
195468719
CY2015Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8635077
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171143919
CY2015Q3 us-gaap Liabilities
Liabilities
2074640
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26604077
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
204637
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
447532
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2074640
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2015Q3 us-gaap Assets
Assets
26604077
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88641
CY2015Q3 us-gaap Assets Current
AssetsCurrent
19949618
CY2015Q3 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
3458450
CY2015Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1065956
CY2015Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3080368
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18883662
CY2015Q3 pvct Accrued Compensation Current
AccruedCompensationCurrent
572436
CY2015Q3 pvct Warrant Liability Current
WarrantLiabilityCurrent
9573
CY2015Q3 pvct Litigation Settlement Remaining Balance Due
LitigationSettlementRemainingBalanceDue
3746667
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15696243
CY2014Q1 pvct Convertible Preferred Stock Share Outstanding
ConvertiblePreferredStockShareOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184796275 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184796275 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
315738
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
25189876
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
440702
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91282
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
181298890
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8131737
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156293810
CY2014Q4 us-gaap Liabilities
Liabilities
994282
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26184158
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
184796
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
437863
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300000 shares
CY2014Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
1120000
CY2014Q2 pvct Annual Cash Bonus Percentage
AnnualCashBonusPercentage
0.70 pure
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
847722
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2014Q4 us-gaap Assets
Assets
26184158
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92171
CY2014Q4 us-gaap Assets Current
AssetsCurrent
19102934
CY2014Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
733333
CY2014Q4 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
3378345
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
978000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3583708
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17391601
CY2014Q4 pvct Warrant Liability
WarrantLiability
146560
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25000 shares
CY2014Q4 pvct Share Based Compensation Arrangement By Share Based Payment Award Options Settlements In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSettlementsInPeriod
2800000 shares
CY2014Q2 pvct Future Payments Ratio Of Contingent Consideration
FuturePaymentsRatioOfContingentConsideration
2 pure
CY2014Q3 pvct Attorneys Fees Awarded By Court In Legal Settlement
AttorneysFeesAwardedByCourtInLegalSettlement
911000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9669940
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
173729010 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
70590
us-gaap Net Income Loss
NetIncomeLoss
-11059230
us-gaap Operating Income Loss
OperatingIncomeLoss
-12367172
us-gaap Investment Income Interest
InvestmentIncomeInterest
4226
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1303716
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2077437
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-70590
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11817967
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3541520
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
238784
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
115645
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
129331
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8322312
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1354508
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
503340
us-gaap Depreciation
Depreciation
5148
pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
4347886
pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
1303716
pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
7470081
pvct Amount Reclassified From Warrant Liability To Equity
AmountReclassifiedFromWarrantLiabilityToEquity
10335619
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
346250
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> 2. <b>Nature of Operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Provectus Biopharmaceuticals, Inc., a Delaware corporation, is a biopharmaceutical company whose planned principal operations is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. The Company&#x2019;s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company&#x2019;s investigational drugs, or sell or license the Company&#x2019;s OTC products or non-core technologies.</p> </div>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12446555
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000315545
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
PROVECTUS BIOPHARMACEUTICALS, INC.
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Trading Symbol
TradingSymbol
PVCT
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
192604128 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6139
us-gaap Net Income Loss
NetIncomeLoss
-14850109
us-gaap Revenues
Revenues
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12099150
us-gaap Operating Income Loss
OperatingIncomeLoss
-14990841
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
87956
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
165439
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-653228
us-gaap Investment Income Interest
InvestmentIncomeInterest
3745
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-136987
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1492061
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6139
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13944755
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7034100
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
685354
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
531991
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7453401
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
79476
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
503340
us-gaap Depreciation
Depreciation
9669
pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
290828
pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
136987
pvct Warrant Issued During Period For Services Value
WarrantIssuedDuringPeriodForServicesValue
79476
pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
13653927
pvct Stock Issued During Period Warrants And Stock Options Exercised Value
StockIssuedDuringPeriodWarrantsAndStockOptionsExercisedValue
290828
CY2014Q1 pvct Aggregate Exercise Price Of Warrants Exercised
AggregateExercisePriceOfWarrantsExercised
2672364
CY2014Q1 pvct Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
3036218 shares
pvct Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
The remaining cash settlement amounts will continue to be repaid to the Company over a period of four years with the second payment due in total by October 2016 and the final payment is expected to be received by October 3, 2019. $80,105 of the settlement discount was amortized as of September 30, 2015.
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
165439
pvct Issuance Of Common Stock And Warrants Pursuant To Regulation D Value
IssuanceOfCommonStockAndWarrantsPursuantToRegulationDValue
1554777
pvct Litigation Settlement Amortization Of Discount
LitigationSettlementAmortizationOfDiscount
80105
pvct Litigation Settlement Present Value Of Discount Remaining
LitigationSettlementPresentValueOfDiscountRemaining
288217
CY2014Q1 pvct Convertible Preferred Stock Shares To Be Converted To Common Stock Shares
ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares
33334 shares
CY2014 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2014Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
900317
CY2014Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
121500 shares
CY2014Q1 pvct Warrants Exercised On Cashless Basis
WarrantsExercisedOnCashlessBasis
12522198 shares
CY2014Q1 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
-1153835
CY2014Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
733000 shares
CY2014Q1 pvct Stock Issued During Period Shares Warrants Exercised On Cashless Basis
StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis
9100824 shares
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1632
CY2015Q1 pvct Gross Proceeds From Sales Of Common Stock And Warrants
GrossProceedsFromSalesOfCommonStockAndWarrants
776000
CY2015Q1 pvct Purchase Price Of Common Stock With Warrants
PurchasePriceOfCommonStockWithWarrants
1.00
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
3693898 shares
CY2015Q1 pvct Percentage Of Common Shares Issuable On Exercise Of Each Warrant
PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant
0.50 pure
CY2015Q1 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
14275
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
3000 shares
CY2015Q1 pvct Stocks Issued During Period Shares Issued For Cash
StocksIssuedDuringPeriodSharesIssuedForCash
776000 shares
CY2014Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2014Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
450002
CY2014Q2 pvct Aggregate Exercise Price Of Warrants Exercised
AggregateExercisePriceOfWarrantsExercised
372000
CY2014Q2 pvct Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
372000 shares
CY2014Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
315000 shares
CY2014Q2 pvct Warrants Exercised On Cashless Basis
WarrantsExercisedOnCashlessBasis
1594082 shares
CY2014Q2 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
186262
CY2014Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
202000 shares
CY2014Q2 pvct Stock Issued During Period Shares Warrants Exercised On Cashless Basis
StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis
915467 shares
CY2015Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53582
CY2015Q2 pvct Gross Proceeds From Sales Of Common Stock And Warrants
GrossProceedsFromSalesOfCommonStockAndWarrants
1011100
CY2015Q2 pvct Purchase Price Of Common Stock With Warrants
PurchasePriceOfCommonStockWithWarrants
1.00
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
1161790 shares
CY2015Q2 pvct Percentage Of Common Shares Issuable On Exercise Of Each Warrant
PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant
0.50 pure
CY2015Q2 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
45568
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
100000 shares
CY2015Q2 pvct Stocks Issued During Period Shares Issued For Cash
StocksIssuedDuringPeriodSharesIssuedForCash
1011100 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q3 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
179088989 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3748547
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3825681
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1410
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1358102
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2299799
CY2014Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
4189
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2014Q3 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
75724
CY2014Q3 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
228500 shares
CY2014Q3 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
-16734
CY2014Q3 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
6000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2015Q3 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
78877 shares
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
204610080 shares
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-5780053
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5778706
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1260
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2696551
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2914375
CY2015Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
24262
CY2015Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2015Q3 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
-2607
CY2015Q3 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
1152135 shares
CY2015Q3 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
-2607
CY2015Q3 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
79500 shares

Files In Submission

Name View Source Status
0001193125-15-366818-index-headers.html Edgar Link pending
0001193125-15-366818-index.html Edgar Link pending
0001193125-15-366818.txt Edgar Link pending
0001193125-15-366818-xbrl.zip Edgar Link pending
d31694d10q.htm Edgar Link pending
d31694dex31.htm Edgar Link pending
d31694dex311.htm Edgar Link pending
d31694dex312.htm Edgar Link pending
d31694dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pvct-20150930.xml Edgar Link completed
pvct-20150930.xsd Edgar Link pending
pvct-20150930_cal.xml Edgar Link unprocessable
pvct-20150930_def.xml Edgar Link unprocessable
pvct-20150930_lab.xml Edgar Link unprocessable
pvct-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending